Management committee

Management committee

Hedi BEN BRAHIM

 

Chief Executive Officer (CEO)

Hedi Ben Brahim has been leading Transgene since January 1st, 2021. Hedi Ben Brahim joined the Company from Institut Mérieux where he was Vice-President for Immunotherapy since 2018. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of the École Polytechnique and the École Nationale Supérieure des Mines de Paris.

Hedi Ben Brahim has been a Director of the Company since 2019.

Committee: Director Member of the Strategy Committee

Chief Executive Officer (CEO)
Eric QUÉMÉNEUR

Eric-Quemeneur

Executive Vice President and Vice President, Research & Development

Eric Quéméneur joined Transgene in September 2014 as Executive Vice President in charge of Research and Development. Before joining Transgene, he spent over 20 years at the CEA (Atomic Energy Commission) where he was Director of research programs and industrial partnerships in the life science division. His responsibilities included: the management of R&D programs and their transition into applications, the management of multidisciplinary teams and the development of national and international alliances. Eric Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France. He is the author of nearly 80 articles published in international scientific journals.

Executive VP, & Chief Scientific Officer (CSO)
Christophe ANCEL

Christophe ANCEL

 

VP, Pharmaceutical Operations & Qualified Pharmacist


Christophe Ancel joined Transgene in 2008, first as Head of Quality Assurance and then as Vice President, Operational Quality. Prior to that, he was a consultant for several international pharmaceutical groups. From 2001 to 2005, he was Head of Quality, Assistant Pharmacist and Interim Responsible Pharmacist for the French production site of E. Lilly. In 2001, he was Director of Quality Assurance and Interim Responsible Pharmacist for a Cardinal Health site. From 1992 to 2000, he worked on Quality Assurance for Alcon Laboratories and was Assistant Pharmacist at the production site. He has international work experience in the areas of production and commercialization of sterile products. Christophe qualified as a Doctor of Pharmacy.

 

VP, Pharmaceutical Operations & Qualified Pharmacist
Steven BLOOM

Chief Business Officer

Steven Bloom joined Transgene in February 2022 as Chief Business Officer. Prior to that, he has held senior leadership roles in both large multi-national corporations and biotech companies and has closed major biotech deals in the field of oncology.

Prior to joining Transgene, Steven was Senior Vice President at Boston Pharmaceuticals. Before that he was Chief Business Officer at Vavotar Life Sciences (formerly known as NantiBodyFc); he held similar roles at Verastem Oncology and Ziopharm Oncology. Earlier in his career he served 18 years at Eli Lilly in key positions in Sales/Marketing and Corporate Affairs in several US locations. Steven holds a BS in Pharmacy from Northeastern University in Boston.

 

Chief Business Officer (CBO)
Maud BRANDELY

Maud

VP Medical Affairs & Chief Medical Officer (CMO) 

Maud Brandely joined Transgene as Chief Medical Officer in March 2016. Maud Brandely was previously Director of Clinical Development at Pierre Fabre Oncologie until February 2016. She was responsible for all clinical trials from Phase I to Phase III. As such, she was involved in the successful registrations of Navelbine oral in breast cancer and NSCLC and vinflunine in transitional cell carcinoma of the urothelial tract. Prior to Pierre Fabre, Maud was Director of Taxotere clinical development at Rhone-Poulenc (RPR, now Sanofi) and was responsible for setting up global registration of clinical studies in both the US and Europe. As such she shared her time between Collegeville and Paris to oversee her US and European teams. Before RPR, she worked at Hoescht-Roussel-Uclaf (now Sanofi) and was involved in the development of cytokines (Il2, IFN) and cytotoxics. Maud is an MD and obtained a PhD in Immunology.

VP Medical Affairs & Chief Medical Officer (CMO)
Jean-Philippe DEL

Jean-Philippe DEL

VP, Chief Financial Officer (CFO)

Jean-Philippe Del became Vice President, Finance at Transgene in 2014, previously serving as Finance Senior Director. He joined the Company in 2005 and has been responsible for management control, accounting and purchasing. Before joining Transgene, he was a financial auditor with Mazars and began his career in 2001 as a financial controller at Kronenbourg Breweries. Jean-Philippe Del has a post-graduate degree in accounting and finance (DESCF) and a master’s degree from the University of Strasbourg.

 

VP, Chief Financial Officer (CFO)
John FELITTI

John FELITTI

VP, General Counsel & Corporate Secretary

John Felitti joined Transgene in March 2016 as General Counsel & Corporate Secretary. Before joining Transgene, he was Associate Vice President, Corporate Law, Finance & Securities Law at Sanofi and previously held other positions in the Sanofi and the Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices of the global U.S. law firm Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. After majoring in economics at Harvard University (AB 1991) and the College of Europe (MA 1993), John Felitti studied law at the University of Michigan (JD 1996) and the University of Paris II – Panthéon (LLM 1997). He also holds a business degree from INSEAD (GEMBA 2015).

 

VP, General Counsel & Corporate Secretary
Gaëlle STADTLER

Gaëlle STADTLER

VP, Human Resources Director

Gaëlle Stadtler became Human Resources Director in January 2021 and joined the Management Committee at the same time. Gaëlle Stadtler joined Transgene as Head of Human Resources and Internal Communications in 2018. Between 2011 and 2017, Gaëlle held the positions of Human Resources Manager at Sensient Flavors, and HR Generalist at L&L Products. She started her career at Mars Inc. as a Talent and Training Coordinator. Gaëlle holds a Master in Management from Skema Business School Lille and a Master 2 HR from EM Strasbourg.

VP, Human Resources Director

 

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits